Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Reports 94-Percent Jump in Q3 Revenue, Though Losses Jump 10 Percent

NEW YORK, Oct. 21 (GenomeWeb News) - CombiMatrix today reported a 94-percent increase in third-quarter revenues atop a jump in R&D spending and widened net losses.


Total receipts for the period ended Sept. 30 increased to $1.5 million from $753,000 year over year, the Acacia unit reported. The brunt of the growth came from product sales and services, which increased to $490,000 in the third quarter 2005 from $68,000 in the prior year. Revenue from government contracts increased to $973,000 from $685,000.


R&D costs increased 34 percent to $1.5 million from $1.1 million in the year-ago period.


Net losses in the third quarter widened almost 10 percent to $3.9 million from $3.5 million, CombiMatrix said.


The unit had around $24.7 million in cash and short-term investments as of Sept. 30.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.